Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14203720 | 1.00 | F2R (0.84) | F2R | |
| SCHEMBL12759523 | 1.00 | F2R (0.84) | F2R | |
| SCHEMBL13513129 | 0.92 | F2R (1.00) | F2R | |
| SCHEMBL14203709 | 0.92 | F2R (1.00) | F2R | |
| SCHEMBL13324645 | 0.92 | F2R (1.00) | F2R | |
| SCHEMBL12831686 | 0.92 | F2R (0.82) | F2R | |
| SCHEMBL11969013 | 0.92 | F2R (1.00) | F2R | |
| SCHEMBL15282339 | 0.92 | F2R (1.00) | F2R | |
| SCHEMBL11994829 | 0.92 | F2R (1.00) | F2R | |
| SCHEMBL11969016 | 0.92 | F2R (1.00) | F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240539-A1 | Preparation and Use of Cyclic Sulfonamide Derivatives as PAR-1 Receptor Antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170224666-A9 | IMMEDIATE-RELEASE TABLET FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | TOPROL ACQUISITION LLC | 2017-08-10 | — | — | US | disclosed |
| US-20160193196-A1 | IMMEDIATE-RELEASE TABLET FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | US | disclosed |
| US-8575351-B2 | Active metabolite of a thrombin receptor antagonist | MERCK SHARP & DOHME CORP. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8329905-B2 | Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate | MERCK SHARP & DOHME CORP. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120302745-A1 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | THIRUVENGADAM TIRUVETTIPURAM K (US) | 2012-11-29 | — | — | US | disclosed |
| US-8273790-B2 | Exo-selective synthesis of himbacine analogs | SCHERING CORPORATION (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120214845-A1 | ACTIVE METABOLITE OF A THROMBIN RECEPTOR ANTAGONIST | TOPROL ACQUISITION LLC | 2012-08-23 | — | — | US | disclosed |
| US-20120142914-A1 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | TOPROL ACQUISITION LLC | 2012-06-07 | — | — | US | disclosed |
| US-8138180-B2 | Exo-selective synthesis of himbacine analogs | SCHERING CORPORATION (US) | 2012-03-20 | — | — | US | disclosed |
| US-7626045-B2 | Synthesis of himbacine analogs | SCHERING CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090281321-A1 | EXO- AND DIASTEREO- SELECTIVE SYNTHESES OF HIMBACINE ANALOGS | SCHERING CORPORATION | 2009-11-12 | — | — | US | disclosed |
| US-7605275-B2 | Cyclization of 1-(1-(diphenylaminocarbonyl-vinyl-)ethyl-oxycarbonyl-vinyl-),5-nitro-)cyclohex-1-ene by heating in a solvent to form an trans-(5,6)ring junction and an endoisomer(cis) isomer of 3-(oxo),6-(nitro),9-diphenylamido-perhydro-4,4a-didehydronaphtho(2,3)furan | SCHERING CORPORATION (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090203925-A1 | SYNTHESIS OF HIMBACINE ANALOGS | SCHERING CORPORATION | 2009-08-13 | — | — | US | disclosed |
| US-7541471-B2 | Synthesis of himbacine analogs | SCHERING CORPORATION (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080194560-A1 | DISINTEGRATION PROMOTERS IN SOLID DOSE WET GRANULATION FORMULATIONS | SCHERING CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080031943-A1 | IMMEDIATE-RELEASE TABLET FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | TOPROL ACQUISITION LLC | 2008-02-07 | — | — | US | disclosed |
| US-20080026050-A1 | SOLID DOSE FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | SCHERING CORPORATION | 2008-01-31 | — | — | US | disclosed |
| US-20080004449-A1 | Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate | TOPROL ACQUISITION LLC | 2008-01-03 | — | — | US | disclosed |
| US-20070238674-A1 | TRA COMBINATION THERAPIES | SCHERING CORPORATION | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194560-A1 | DISINTEGRATION PROMOTERS IN SOLID DOSE WET GRANULATION FORMULATIONS | SP1, TMPRSS2, GPR39 | F2R 11/4885 |
| US-20080004449-A1 | Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate | F2, F2R, PTAFR | F2R 2/4885 |
| US-20170224666-A9 | IMMEDIATE-RELEASE TABLET FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | F2R, F2RL1, TBXA2R | F2R 1/4885 |
| US-20160193196-A1 | IMMEDIATE-RELEASE TABLET FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | F2R, F2RL1, TBXA2R | F2R 1/4885 |
| US-20080026050-A1 | SOLID DOSE FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | F2R, F2RL1, TBXA2R | F2R 1/4885 |
| US-20080031943-A1 | IMMEDIATE-RELEASE TABLET FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST | F2R, F2RL1, TBXA2R | F2R 1/4885 |
| US-20090203925-A1 | SYNTHESIS OF HIMBACINE ANALOGS | BDKRB1, HTR3B, HTR1B | F2R 11/4885 |
| US-20170240539-A1 | Preparation and Use of Cyclic Sulfonamide Derivatives as PAR-1 Receptor Antagonists | F2R, PRSS1, F2RL1 | F2R 1/4885 |
| US-20120214845-A1 | ACTIVE METABOLITE OF A THROMBIN RECEPTOR ANTAGONIST | F2R, F2RL1, F2RL3 | F2R 1/4885 |
| US-20120302745-A1 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | CHKB, BDKRB1, EDNRB | F2R 70/4885 |
| US-20090281321-A1 | EXO- AND DIASTEREO- SELECTIVE SYNTHESES OF HIMBACINE ANALOGS | EDNRA, EDNRB, NMBR | F2R 24/4885 |
| US-20120142914-A1 | EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS | CHKB, BDKRB1, EDNRB | F2R 70/4885 |
| US-20070238674-A1 | TRA COMBINATION THERAPIES | EDNRA, EDNRB, TBXA2R | F2R 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.